Antibody Design
Elevating antibody therapeutics with data-driven AI. Building on advances in generative and language model-based methods for explorative CDR backbone design, combined with deimmunization and paratope-based functional antibody classification, our approach aims to illuminate the blueprint of epitope-specific antibody design.
Protein/Peptide Binder Design
De novo design of proteins with desirable functions. Leveraging advanced deep learning methods for generative protein backbone design, exploration of protein conformational space, and accurate predictions of protein-protein interactions, combined with robust molecular dynamics simulations, our approach crafts therapeutic solutions that redefine the landscape of intricate protein-based drug development.
Small-Molecule Drug Design
Engineering at the molecular scale for drug-target selectivity. Through seamless integration of AI-driven exploration of protein conformational heterogeneity with generative drug designs aided by expertise in medicinal chemistry, our high throughput virtual screening approach guarantees swift and inventive drug candidate discovery.
news 설정이 존재하지 않습니다
News
Up-To-Date News about Arontier which is an artificial intelligence-driven drug discovery start-up company using bioinformatics, pharmacogenomics for incurable and rare diseases.
Our partners
ADDRESS : 15F, 241, Gangnam-daero, Seocho-gu, Seoul, Republic of Korea
Copyright 2018~2021 ARONTIER. All Rights Reserved.